These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35864956)

  • 1. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
    Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
    Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
    [No Abstract]   [Full Text] [Related]  

  • 2. High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1.
    Li C; Chen X; Wu J; Heng S; Xu Z; Gu H; Lin E; Wang J; Shan Y
    Biochem Biophys Res Commun; 2024 Nov; 734():150782. PubMed ID: 39378786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
    Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
    Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
    Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
    J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
    Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
    Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
    Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
    Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
    Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
    Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
    Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
    Wei L; Lee D; Law CT; Zhang MS; Shen J; Chin DW; Zhang A; Tsang FH; Wong CL; Ng IO; Wong CC; Wong CM
    Nat Commun; 2019 Oct; 10(1):4681. PubMed ID: 31615983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
    Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
    Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma.
    Xie P; Wu M; Wang H; Zhang B; Zhang Z; Yan J; Yu M; Yu Q; Zhao Y; Huang D; Xu M; Xu W; Li H; Xu Y; Xiao Y; Guo L
    Oncogene; 2024 Oct; 43(42):3108-3120. PubMed ID: 39251847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
    Hu Q; Hu X; Zhang L; Zhao Y; Li L
    Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR activation limits the response of liver cancer to lenvatinib.
    Jin H; Shi Y; Lv Y; Yuan S; Ramirez CFA; Lieftink C; Wang L; Wang S; Wang C; Dias MH; Jochems F; Yang Y; Bosma A; Hijmans EM; de Groot MHP; Vegna S; Cui D; Zhou Y; Ling J; Wang H; Guo Y; Zheng X; Isima N; Wu H; Sun C; Beijersbergen RL; Akkari L; Zhou W; Zhai B; Qin W; Bernards R
    Nature; 2021 Jul; 595(7869):730-734. PubMed ID: 34290403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.
    Ao J; Chiba T; Shibata S; Kurosugi A; Qiang N; Ma Y; Kan M; Iwanaga T; Sakuma T; Kanzaki H; Kanayama K; Kojima R; Kusakabe Y; Nakamura M; Saito T; Nakagawa R; Kondo T; Ogasawara S; Suzuki E; Muroyama R; Kato J; Mimura N; Kanda T; Maruyama H; Kato N
    Biochem Biophys Res Commun; 2021 Apr; 549():171-178. PubMed ID: 33676186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma.
    Hao SH; Ma XD; Xu L; Xie JD; Feng ZH; Chen JW; Chen RX; Wang FW; Tang YH; Xie D; Cai MY
    Drug Resist Updat; 2024 Mar; 73():101052. PubMed ID: 38262246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation.
    Yan S; Chen L; Zhuang H; Yang H; Yang Y; Zhang N; Liu R
    Int J Biol Sci; 2024; 20(8):3046-3060. PubMed ID: 38904018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma.
    Xu MH; Zheng YM; Liang BG; Xu WX; Cao J; Wang P; Dong ZY; Zhou CH; Sun HC; Ren N; Ke AW; Shen YH
    Int J Biol Sci; 2024; 20(9):3269-3284. PubMed ID: 38993552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.